BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Annamalai B, Parsons N, Nicholson C, Obert E, Jones B, Rohrer B. Subretinal Rather Than Intravitreal Adeno-Associated Virus-Mediated Delivery of a Complement Alternative Pathway Inhibitor Is Effective in a Mouse Model of RPE Damage. Invest Ophthalmol Vis Sci 2021;62:11. [PMID: 33830174 DOI: 10.1167/iovs.62.4.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Dreismann AK, Hallam TM, Tam LC, Nguyen CV, Hughes JP, Ellis S, Harris CL. Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway. Immunological Reviews 2022. [DOI: 10.1111/imr.13149] [Reference Citation Analysis]
2 Gibson BG, Cox TE, Marchbank KJ. Contribution of animal models to the mechanistic understanding of Alternative Pathway and Amplification Loop (AP/AL)-driven Complement-mediated Diseases. Immunol Rev 2022. [PMID: 36203396 DOI: 10.1111/imr.13141] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Akter T, Annamalai B, Obert E, Simpson KN, Rohrer B. Dabigatran and Wet AMD, Results From Retinal Pigment Epithelial Cell Monolayers, the Mouse Model of Choroidal Neovascularization, and Patients From the Medicare Data Base. Front Immunol 2022;13:896274. [DOI: 10.3389/fimmu.2022.896274] [Reference Citation Analysis]
4 Udsen M, Tagmose C, Garred P, Nissen MH, Faber C. Complement activation by RPE cells preexposed to TNFα and IFNγ. Experimental Eye Research 2022. [DOI: 10.1016/j.exer.2022.108982] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]